Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

273.86USD
4:00pm EDT
Change (% chg)

$4.41 (+1.64%)
Prev Close
$269.45
Open
$271.10
Day's High
$277.38
Day's Low
$270.78
Volume
807,178
Avg. Vol
604,465
52-wk High
$370.53
52-wk Low
$244.31

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $55,461.16
Shares Outstanding(Mil.): 211.56
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 13.79 29.67 32.21
EPS (TTM): 19.54 -- --
ROI: 20.73 13.44 13.05
ROE: 32.41 15.16 14.90

Biogen's revenue misses as Spinraza sales disappoint

Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment.

Apr 24 2018

UPDATE 3-Biogen's revenue misses as Spinraza sales disappoint

* Biogen shares pare losses (Adds conference call, analysts comments; updates shares)

Apr 24 2018

Biogen quarterly profit jumps on higher Spinraza sales

April 24 Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.

Apr 24 2018

BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion

* QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR

Apr 24 2018

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

Apr 20 2018

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

Apr 20 2018

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

Apr 20 2018

Biogen to pay $1 billion to Ionis in new partnership

April 20 Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

Apr 20 2018

Samsung C&T mulling raising up to $2.8 bln to buy stake in biopharma affiliate: MBC

SEOUL Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.

Apr 09 2018

Samsung C&T mulling raising up to $2.8 bln to buy stake in biopharma affiliate - MBC

SEOUL, April 9 Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.

Apr 09 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $128.01 +1.25
Pfizer Inc. (PFE.N) $36.85 +0.17
Novartis AG (NOVN.S) CHF76.10 +0.86
Merck & Co., Inc. (MRK.N) $59.41 -0.22
Roche Holding Ltd. (ROG.S) CHF218.10 +0.35
Roche Holding Ltd. (RO.S) CHF223.00 +0.40
Bayer AG (BAYGn.DE) €97.34 -0.13
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.31 +0.44
GlaxoSmithKline plc (GSK.L) 1,436.80 +24.60

Earnings vs. Estimates